$Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma results of a meta-analysis$

Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma results of a meta-analysis

Combinations of cytotoxic chemotherapy with estramustine phosphate (EMP), a nornitrogen mustard-estrogen conjugate, are used to treat patients with hormone-refractory prostate carcinoma (HRPC). However, thromboembolic events (TE), including deep venous thrombosis (DVT), pulmonary embolism, stroke, m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2004-12, Vol.101 (12), p.2755-2759
Hauptverfasser:	LUBINIECKI, Gregory M, BERLIN, Jesse A, WEINSTEIN, Rachel B, VAUGHN, David J
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Blood and lymphatic vessels Carcinoma - complications Carcinoma - drug therapy Cardiology. Vascular system Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Drug Resistance, Neoplasm Estramustine - administration & dosage Estramustine - adverse effects Humans Male Medical sciences Prostatic Neoplasms - complications Prostatic Neoplasms - drug therapy Risk Factors Thromboembolism - chemically induced Tumors Venous Thrombosis - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!